Delcath Systems, Inc. (NASDAQ:DCTH) Receives Consensus Rating of “Moderate Buy” from Brokerages

Delcath Systems, Inc. (NASDAQ:DCTH) has been given a consensus recommendation of “Moderate Buy” by the six analysts that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation and five have issued a buy recommendation on the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $22.40.

Several equities analysts have commented on the stock. Stephens decreased their target price on shares of Delcath Systems from $25.00 to $18.00 and set an “overweight” rating on the stock in a report on Wednesday, November 5th. Wall Street Zen upgraded shares of Delcath Systems from a “hold” rating to a “buy” rating in a research report on Saturday. Weiss Ratings restated a “sell (d+)” rating on shares of Delcath Systems in a research report on Monday, December 29th. BTIG Research restated a “buy” rating and set a $23.00 target price on shares of Delcath Systems in a research note on Tuesday, November 4th. Finally, HC Wainwright reiterated a “buy” rating and issued a $30.00 price target on shares of Delcath Systems in a research note on Friday.

Delcath Systems Trading Up 1.3%

Shares of DCTH stock opened at $10.34 on Friday. The stock has a market cap of $365.11 million, a P/E ratio of 1,034.00 and a beta of 0.39. Delcath Systems has a 1 year low of $8.12 and a 1 year high of $18.23. The stock has a 50 day simple moving average of $9.60 and a 200 day simple moving average of $10.64.

Delcath Systems (NASDAQ:DCTH) last announced its quarterly earnings data on Tuesday, November 4th. The company reported $0.02 earnings per share for the quarter, meeting the consensus estimate of $0.02. The firm had revenue of $20.56 million during the quarter, compared to analysts’ expectations of $23.22 million. Delcath Systems had a return on equity of 7.02% and a net margin of 1.50%. Analysts forecast that Delcath Systems will post -0.79 EPS for the current year.

Delcath Systems announced that its board has authorized a stock repurchase plan on Thursday, November 20th that allows the company to repurchase $25.00 million in outstanding shares. This repurchase authorization allows the company to purchase up to 8.6% of its shares through open market purchases. Shares repurchase plans are typically a sign that the company’s leadership believes its stock is undervalued.

Insider Transactions at Delcath Systems

In other Delcath Systems news, CEO Gerard J. Michel bought 11,500 shares of the stock in a transaction on Tuesday, November 11th. The stock was purchased at an average price of $8.53 per share, with a total value of $98,095.00. Following the completion of the purchase, the chief executive officer owned 330,834 shares in the company, valued at $2,822,014.02. The trade was a 3.60% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. 17.40% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Delcath Systems

A number of hedge funds have recently made changes to their positions in the stock. USA Financial Formulas acquired a new position in Delcath Systems during the 2nd quarter worth approximately $25,000. California State Teachers Retirement System bought a new stake in shares of Delcath Systems during the second quarter worth $26,000. Russell Investments Group Ltd. acquired a new position in shares of Delcath Systems during the third quarter worth $29,000. Tower Research Capital LLC TRC acquired a new position in shares of Delcath Systems during the second quarter worth $40,000. Finally, Ameritas Investment Partners Inc. bought a new position in shares of Delcath Systems in the 2nd quarter valued at $42,000. 61.12% of the stock is currently owned by institutional investors and hedge funds.

Delcath Systems Company Profile

Delcath Systems, Inc is a specialty pharmaceutical and medical technology company focused on the development and commercialization of its proprietary Hepatic CHEMOSAT® Delivery System, designed to deliver high-dose chemotherapeutic agents directly to the liver while minimizing systemic exposure. The company’s core technology performs isolated hepatic perfusion, enabling oncologists to administer concentrated melphalan to patients with primary and metastatic liver tumors, including those arising from ocular melanoma.